Lower Urinary Tract Symptoms (LUTS): Initial Choices and Final Outcomes

Proceedings of a Satellite Symposium held at the XVIth Congress of the European Association of Urology
Geneva, April 7, 2001

Guest Editor
W. Artibani, Verona, Italy

13 figures and 5 tables, 2001
Supported by an unconditional educational grant from Yamanouchi Europe BV and Boehringer Ingelheim GmbH. Editorial support was provided by Ismar Healthcare NV. The views and opinions expressed in this professional education supplement are those of the authors and do not necessarily reflect the views of Yamanouchi Europe BV, Boehringer Ingelheim GmbH or Ismar Healthcare NV.

Drug Dosage
The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Contents

1 Introduction
Artibani, W. (Verona)

5 Potential Mechanisms of Action of Superselective $\alpha_1$-Adrenoceptor Antagonists
Price, D. (Shreveport, La.)

12 Lower Urinary Tract Symptoms: What Are the Implications for the Patients?
Scarpa, R.M. (Orbassano)

21 Initial Choices and Final Outcomes in Lower Urinary Tract Symptoms
Speakman, M.J. (Taunton)